Chemotherapy, the standard cancer treatment, is largely prescribed by informed guesses. Because this inaccurate method kills both cancerous and healthy cells, patients suffer from nasty side effects and don't usually get a drug that works for them the first time, if they get one that works at all. We're developing a targeted therapy for a highly lethal leukemia and a diagnostic to determine which patients will respond well to the drug. We're about to start Phase 1b/2 of clinical trials. [Read More]
A safe is a Simple Agreement for Future Equity. An investor makes a cash investment in a company, but gets company stock at a later date, in connection with a specific event. A safe is not a debt instrument, but is intended to be an alternative to convertible notes that is beneficial for both companies and investors.
June 30, 2018
September 28, 2018
Founder and CEO
Anti-cancer Crusader! Principal Investigator for NMI's 6 grants. PhD -Biochemistry, MBA, Marathoner
Chief Sceintific Officer
Dr. Davis is certified as a Diplomate, American College of Veterinary Pathologists and has over 20 years of research experience in female endocrine and reproductive pathology and cancers.
William "Sandy" White
William S. White is the former CEO of Icon Bioscience and has over 25 years of pharma industry experience, including executive leadership, global development/licensing, R&D and commercialization.
Senior VP, Operations
Dave has over 25 years of experience in cGMP large and small molecule manufacturing operations, process development/scale-up, facility design and construction, and R&D.
Allison B. Morse
Director of Clinical Affairs
Allison has more than 15 years of experience caring for women with cancer throughout the course of their disease. She has a Master’s in Public Health and a Master’s of Science in Nursing.
There are no additional research reports currently.